SAN FRANCISCO (MarketWatch) -- Amgen Inc. after Wednesday's closing bell introduced Amgen Oncology Assistance, a financial assistance program that will include a cap on out-of-pocket co-payments for ...

Amgen launched a direct-to-patient program Oct. 6 to offer its cholesterol medication Repatha at a reduced price. The AmgenNow program will provide Repatha for $239 per month — nearly 60% below the ...

Please provide your email address to receive an email when new articles are posted on . Evolocumab will be made available to eligible patients via a new direct-to-consumer program. The PCSK9 inhibitor ...

Amgen has launched a late-stage program to test the feasibility of switching patients from weekly GLP-1 injections to its own ...

Amgen is discontinuing a lung disease program after its investigational small molecule failed to hit any of the primary or secondary endpoints in a midstage study. The asset at play is fipaxalparant, ...

The Amgen Foundation is supporting an online competition with Ashoka’s Changemakers to find the best solutions that elevate patients’ voices to improve health outcomes globally. The Patients| Choices| ...

The FDA has renewed calls for Amgen’s Tavneos to be pulled from the market, saying it has discovered new evidence that study ...

Amgen Inc. (NASDAQ:AMGN) and Kyowa Kirin released preliminary topline results from the ASCEND study evaluating rocatinlimab in adults and adolescents with moderate to severe atopic dermatitis (AD) on ...

The firm said that after reviewing its oncology portfolio and seeing the PRMT5 inhibitor's initial activity, it decided to discontinue its development.

THOUSAND OAKS, Calif., Oct. 7, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new combination study results from the Phase 1b CodeBreaK 101 study, a comprehensive global master protocol ...

Pharmaceutical companies are undergoing a profound transformation. No longer confined to merely developing treatments, companies are assuming a partnership role to collaborate with healthcare ...

Specialty pharmacy workflows must account for longer, more complex affordability calls, with copay-shock interactions ...